These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15623630)

  • 1. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.
    Yang Q; Kiernan CM; Tian Y; Salwen HR; Chlenski A; Brumback BA; London WB; Cohn SL
    Clin Cancer Res; 2007 Jun; 13(11):3191-7. PubMed ID: 17545522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of RASSF1a in uveal melanoma.
    Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
    Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
    Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
    Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
    Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
    Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
    Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
    Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.